Express News | State Council meeting: Deploy measures to deepen the reform of Pharmaceutical and medical instruments regulatory system to promote high-quality development of the pharmaceutical industry.

BreakingsDec 24, 2024 19:10

The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19, 2024 22:27

UBS Group: The price reduction of the tenth round of collective procurement of Pharmaceuticals exceeded expectations, showing a cautious attitude towards the China generic drug market.

UBS Group released a research report stating that the tenth batch of national Pharmaceutical procurement in the mainland involves 62 types of Pharmaceuticals, with 385 products eligible for selection. Although the government has not disclosed the price reduction situation, according to Statistics, this time the reduction exceeds expectations, reaching 80% to 96%, and it is believed to be the largest reduction in history. The results of the Pharmaceutical procurement will be comprehensively implemented nationwide starting from April next year and will remain effective until the end of 2027. Overall, UBS Group believes that the results of the tenth batch of national Pharmaceutical procurement reflect China's tightening of the basic Medical Insurance Fund, and the government has also increased support for new drugs. Looking ahead, the bank holds a cautious attitude towards the prospects of China's generic drug market, and also anticipates.

AASTOCKSDec 19, 2024 09:49

HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.

HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.

Zhitong FinanceDec 13, 2024 07:20

The tenth batch of Pharmaceutical centralized procurement in the mainland is about to begin bidding, with 62 types of Pharmaceuticals included in the national procurement.

The national Pharmaceutical procurement declaration information public conference will be held today (12th) in Shanghai, signaling the upcoming opening of bids for the tenth national Pharmaceutical concentrated procurement. This national procurement includes 62 types of Pharmaceuticals. Since the pilot for concentrated Pharmaceutical procurement launched in 2018 in four direct-controlled municipalities and seven sub-provincial cities, the process has gradually normalized. In recent years, it has generally occurred twice a year, while the tenth batch of procurement is the only national procurement for 2024. This national procurement includes 62 types of Pharmaceuticals, covering various disease areas such as cardiovascular and cerebrovascular, digestive, tumors, and metabolism, with more than half being injections sold through Hospital channels. The procurement cycle for each variety is determined by the selection results.

AASTOCKSDec 12, 2024 10:32

Express News | CITIC Construction Investment: Optimistic about investment opportunities in the pharmaceutical industry in 2025, focusing on new volume and industry integration opportunities

BreakingsDec 12, 2024 07:38